China Lung Cancer Screening Market Forecast to Reach US$ 1.3 Bn by 2032, Growing Rapidly

The China lung cancer screening market is poised for substantial growth over the next decade, with projections indicating an increase from US$ 616.2 million in 2025 to US$ 1,295.5 million by 2032, representing a compound annual growth rate (CAGR) of approximately 11.2% during the forecast period. Lung cancer continues to pose a critical public health challenge in China, responsible for over 700,000 deaths annually. Despite advancements in therapeutic approaches, early diagnosis remains elusive, driving the need for robust screening strategies. Low-Dose Computed Tomography (LDCT) has emerged as the preferred screening modality, enabling early detection and improving survival outcomes. National health policies increasingly prioritize lung cancer screening, establishing a supportive environment for market expansion.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35427

Key Industry Highlights

Government-backed initiatives are accelerating the adoption of LDCT-based screening programs, with increased focus on high-risk populations. Collaborations between artificial intelligence (AI) developers and healthcare providers are enhancing diagnostic precision while alleviating the workload of radiologists. LDCT is anticipated to capture nearly 71.4% of the diagnostic market by 2025, reflecting its efficacy in early-stage lung cancer detection. Regionally, provinces such as Shandong, Sichuan, and Jiangsu are emerging as key markets due to proactive implementation of opportunistic LDCT screening. Non-small cell lung cancer (NSCLC) dominates the epidemiological landscape, driven by rising adenocarcinoma incidence linked to environmental pollutants and indoor air exposure.

Market Dynamics

Driver: Government initiatives represent the primary catalyst for market growth. The National Cancer Screening Program (NCSP) and provincial-level directives have incorporated lung cancer into public health screening agendas. Funding mechanisms, guideline development, and policy support are fostering widespread adoption. Programs are tailored to Chinese demographics, considering non-smoking adenocarcinoma prevalence, population aging, and regional risk factors, thus ensuring high acceptance among practitioners and insurers. Inclusion of lung cancer screening in public insurance coverage further strengthens accessibility, although current funding primarily covers initial high-risk screenings.

Restraint: Despite policy support, uptake of lung cancer screening remains uneven, constraining market expansion. Studies highlight low compliance, even among free or subsidized programs. Barriers include out-of-pocket costs for follow-ups, logistical challenges, low health literacy, and distrust in healthcare institutions. High false-positive rates, documented at nearly 68.8% in nationwide cohorts, create additional burdens in terms of anxiety, follow-up procedures, and healthcare expenditure, dampening enthusiasm for repeated screening.

Opportunity: AI integration offers significant growth potential. Real-world studies in China demonstrate that AI-assisted LDCT analysis enhances diagnostic accuracy, achieving detection rates exceeding 93% for lung nodules. Deep learning models have shown sensitivity between 75% and 94% and specificity between 82% and 91%, significantly outperforming conventional methods. AI implementation is expanding to over 160 hospitals nationwide, optimizing early-stage detection, particularly for non-smoking populations traditionally underrepresented in Western screening protocols. Such technological advancements are expected to drive market penetration and improve patient outcomes.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/china-lung-cancer-screening-market.asp

Category-wise Analysis

Cancer Type Insights: The market is segmented by cancer type into NSCLC and small cell lung cancer (SCLC). NSCLC is projected to account for 82.4% of the market in 2025, reflecting its dominant incidence rate and increasing prevalence of adenocarcinoma. SCLC, while less common, is anticipated to register a notable CAGR due to its strong association with smoking and early metastasis, particularly in provinces such as Hebei.

Diagnosis Insights: LDCT and chest X-ray constitute the primary diagnostic categories. LDCT is projected to dominate with a 71.4% market share in 2025, supported by its high sensitivity, accessibility, and cost-effectiveness. Chest X-ray, while less precise, remains a relevant screening tool, particularly in community health programs, enhancing public awareness and serving as a comparator for newer modalities. Economic modeling confirms LDCT's superiority in reducing lung cancer mortality compared to chest X-rays, further consolidating its market dominance.

Regional Insights

Shandong: Shandong province exhibits a high lung cancer burden, with age-standardized incidence and mortality rates exceeding national averages. Adoption of LDCT has been reinforced through provincial health policies aligned with national guidelines, targeting high-risk groups with structured screening protocols and follow-up mechanisms.

Sichuan: Accessibility challenges persist despite urban centers providing convenient LDCT services. Surveys indicate that only 34.7% of high-risk adults complete annual screening, highlighting room for improvement in rural and minority regions. Media campaigns, navigation support, and express diagnostic pathways have demonstrated modest increases in uptake, offering a blueprint for enhanced implementation.

Jiangsu: Developed urban centers in Jiangsu show higher screening participation compared to rural counterparts. Age-period-cohort modeling predicts stable or slightly declining lung cancer incidence in males and rural residents, while urban females remain consistently affected. Proactive adoption of national LDCT screening frameworks and efficient follow-up systems supports steady market growth.

Competitive Landscape

The China lung cancer screening market encompasses a mix of public institutions, domestic start-ups, and multinational medical imaging companies. Key market players are focused on expanding LDCT access, leveraging AI capabilities, and addressing regional disparities through mobile CT units and tele-radiology platforms. Domestic manufacturers are rapidly scaling production to meet government-supported demand, while international players compete in technology provision and clinical validation services.

Key Players

Leading stakeholders in the market include Biodesix, GE Healthcare, DELFI Diagnostics, Shenzhen Mindray Bio-Medical Electronics, Canon Medical Systems, Siemens Healthineers, Medtronic, Koninklijke Philips, Freenome Holdings, and Shanghai United Imaging Healthcare. Companies are increasingly emphasizing research collaboration, AI integration, and regional penetration strategies to strengthen their competitive positioning.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35427

Market Segmentation

By Cancer Type

Non-small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)

By Diagnosis

Low Dose Spiral CT Scan
Chest X-ray

By End-use

Hospitals and Clinics
Diagnostic Centers
Others

By Province

Anhui
Guizhou
Guangdong
Shandong
Jiangsu
Others

Recent Developments

In April 2025, research at the Guangzhou Institute of Respiratory Disease highlighted the efficacy of LDCT in detecting lung cancer in non-smokers, reinforcing the modality's role in high-risk population screening.

In January 2025, Sichuan University assessed urban resident awareness, revealing that only 23.88% of individuals had adequate knowledge regarding lung cancer, underscoring the importance of education and outreach in market development.

Future Outlook

The China lung cancer screening market is set to experience robust growth driven by policy support, technological innovation, and rising demand for early detection. AI-assisted LDCT analysis, expanding insurance coverage, and targeted outreach in high-risk populations are expected to improve compliance and diagnostic precision. While challenges related to false-positive rates and regional disparities persist, ongoing efforts to optimize screening protocols and integrate advanced imaging solutions provide a promising trajectory. By 2032, market expansion will be underpinned by both public health imperatives and commercial opportunities, positioning China as a global leader in lung cancer early detection initiatives.

Read More Related Reports:

Cartilage Repair Market https://www.persistencemarketresearch.com/market-research/cartilage-repair-market.asp
Hydrogel-based Drug Delivery System Market https://www.persistencemarketresearch.com/market-research/hydrogel-based-drug-delivery-system-market.asp
US Assisted Living Facility Market https://www.persistencemarketresearch.com/market-research/us-assisted-living-facility-market.asp
US Assisted Reproductive Technology Market https://www.persistencemarketresearch.com/market-research/us-assisted-reproductive-technology-market.asp
Electronic Health Records Market https://www.persistencemarketresearch.com/market-research/electronic-health-records-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.